A detailed history of Octagon Capital Advisors LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 350,000 shares of APLS stock, worth $10 Million. This represents 3.1% of its overall portfolio holdings.

Number of Shares
350,000
Previous 200,000 75.0%
Holding current value
$10 Million
Previous $11.8 Million 14.21%
% of portfolio
3.1%
Previous 1.84%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $2.81 Million - $4.41 Million
73,900 Added 2.63%
2,880,880 $111 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $7.01 Million - $12.2 Million
188,680 Added 7.21%
2,806,980 $168 Million
Q2 2023

Aug 14, 2023

SELL
$76.68 - $93.31 $48.4 Million - $58.9 Million
-631,700 Reduced 19.44%
2,618,300 $239 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $4.19 Million - $6.03 Million
90,000 Added 2.85%
3,250,000 $214 Million
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $24.9 Million - $35.2 Million
576,941 Added 22.34%
3,160,000 $163 Million
Q2 2022

Aug 15, 2022

BUY
$35.07 - $59.21 $8.52 Million - $14.4 Million
243,000 Added 10.38%
2,583,059 $117 Million
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $11.3 Million - $17.3 Million
319,148 Added 15.79%
2,340,059 $119 Million
Q4 2021

Feb 14, 2022

BUY
$30.74 - $49.16 $13.1 Million - $20.9 Million
425,000 Added 26.63%
2,020,911 $95.5 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $10.7 Million - $23.7 Million
339,646 Added 27.04%
1,595,911 $52.6 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $29 Million - $45.9 Million
707,891 Added 129.09%
1,256,265 $79.4 Million
Q4 2020

Feb 16, 2021

BUY
$30.79 - $57.2 $16.9 Million - $31.4 Million
548,374 New
548,374 $31.4 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.14B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.